Unfortunately, for some people, this can result in super negative side effects like nausea, vomiting, and diarrhea - one study reported that 50% of patients taking GLP-1 agonists experienced nausea while taking them
[26] [27] Retatrutide could potentially be considered for this route given its novel mechanism, though no ILAP designation has been announced and eligibility would need to be assessed formally by the MHRA
NHLBIPatricia Noel, Robert Smith
Its important to note that not everyone will experience these side effects, and they often diminish over time
Metformin, acarbose, empagliflozin, and exenatide were associated with mild weight loss (less than 3.2% of initial weight)
Health Canada authorization does not automatically trigger formulary listing